SLC5A2 and hydrops fetalis: Furthermore, as both HF and the subclinical forms of HF are amongst the earliest vascular complications seen when following up diabetic patients who do not have CVD at baseline [48], it may be suggested that these patients in CVD-REAL benefited from the early use of SGLT2 inhibitors.